Revisiting use of growth factors in myelodysplastic syndromes

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1081-1091

  Newman, Kam ^a   Maness Harris, Lori ^b   El Hemaidi, Ihab ^c   Akhtari, Mojtaba ^b  

^a Jamaica Hospital Medical Center   (Jamaica)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Anemia; Csf; Erythropoiesis stimulating agents; G; Myelodysplastic syndromes

Indexed keywords

ERYTHROPOIETIN; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; ROMIPLOSTIM; THROMBOPOIETIN;

ANEMIA; DRUG COMBINATION; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA;

ANEMIA; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 84873032058     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1081     Document Type: Review

References (126)

1. Albitar M, Manshouri T, Shen Y, et al (2002). Myelodysplastic syndrome is not merely "preleukemia". Blood, 100, 791-8.
2. Akhtari M (2011). When to treat myelodysplastic syndromes. Oncology, 25, 480-6.
3. Balleari E, Rossi E, Clavio M, et al (2005). Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol, 85, 174-80.
4. Barzi A, Sekeres MA (2010). Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleveland Clin J med, 77, 37-44.
5. Bennett JM, Catovsky MT, Flandrin DAG, Galton HR, Sultan (1982). Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 51, 189-99.
6. Beekman R, Touw IP (2010). G-CSF and its receptor in myeloid malignancy. Blood, 115, 5131-36.
7. Bernasconi C, Paolo Alessandrino E, Bonfichi M, Lazzarino M, et al (1998). Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukemia evolving from MDS. Br J Haematol, 102, 678-83.
8. Bernell P, Kimby E, Hast R (1994). Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia, 8, 1631-39.
9. Bessho M, Jinnai I, Matsuda A, Saito M, Hirashima K (1990). Improvement of anaemia by recombinant eryhtropoietin in patients with myelodysplastic syndromes and aplastic anaemia. Int J Cell Cloning, 8, 445-58.
10. Bowen D, Culligan D, Jowitt S, et al (2003). Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol, 120, 187-200.
11. Bowen DT (2006). Hematopoietic growth factors. In: Deeg HJ, Bowen DT, Gore SD, Haferlach T, Le Beau MM, Niemeyer C (eds). Hematologic Malignancies: Myelodysplastic Syndromes, Springer, ?, 99-109.
12. Brito-Babapulle F, Lord JAD, Whitmore DN (1989). Treatment of RAEB-t with intensive chemotherapy and GM-CSF. Leuk Res, 13, 605-7.
13. Bryan J, Jabbour E, Prescott H, et al (2010). Current and future management options for myelodysplastic syndrome. Drugs, 70, 1381-94.
14. Casadevall N, Durieux P, Dubois S, et al (2004). Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood, 91, 179-88.
15. Christopher MJ, Link DC (2007). Regulation of neutrophil hemostasis. Curr Opin Hematol, 14, 3-8.
16. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A, (1992). Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood, 80, 2012-20.
17. Erslev AJ, Erythropoietin (1991). N Engl J Med, 324, 1339-44.
18. Frisan E, Pawlikowska P, Pierre-Eugene C, et al (2010).p-ERK1/2 is a predictive factor of response to erythropoiesisstimulating agents in low/int-1 myelodysplastic syndrome. Haematologica, 95, 1964-8.
19. Garcia-Manero G (2011). Nontransplantation options for patients with myelodysplastic syndromes. Biol Blood Marrow Transplant, 17, 9-10.
20. Garcia-Manero G (2011). Myelodysplastic syndromes: update on diagnosis, risk-stratification, and management. Am J Hematol, 86, 491-8.
21. Garcia-Manero G, Shan J, Faderl S, et al (2008). A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia, 22, 538-43.
22. Geissler RG, Schulte P, Ganse A (1997). Treatment with growth factors in myelodysplastic syndromes. PatholBiol, 45, 656-7.
23. Golshayan AR, Jin T, Maciejewski J, et al (2007). Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol, 137, 125-32.
24. Gotlib J, Greenberg PL (2005). Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy. In: Greenberg PL (ed): Myelodysplastic syndromes. Cambridge University Press, Cambridge, UK, 209-42.
25. Gotlib J, Lavori P, Quesada S, et al (2009). A Phase II intra-patient dose-escalation trial of weight-based darbEPOetinalfa with or without granulocyte colony-stimulating factor in myelodysplastic syndromes. Am J Hematol, 84, 15-20.
26. Greenberg P, Cox C, LeBeau MM, et al (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-88.
27. Greenberg PL, Garcia-Manero G, Moore MR, et al (2009). Efficacy and safety of Romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. American Society of Hematology Annual Metting abstract number 1769.
28. Greenberg PL (2010). Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol, 150, 131-43.
29. Greenberg PL, Negrin RS, Ginzton N (1992). In vitro-in vivo correlations of erythroid responses to G-CSF plus erythropoietin in myelodysplastic syndromes. ExpHematol, 20, 733.
30. Greenberg PL, Sun Z, Miller KB, et al (2009). Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood, 114, 2393-400.
31. Greenberg P, Taylor K, Larson R, et al (1993). Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood, 82, 196.
32. Greenbaum AM, Link DC (2011). Mechanisms of G-CSFmediated hematopoietic stem and progenitor mobilization. Leukemia, 25, 211-7.
33. Gregory T, Yu C, Ma A, et al (1999). GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood, 94, 87-96.
34. Gurion R, Shacham Abulafia A, Shpilberg O, Raanani P (2011). The use of myeloid colony-stimulating factors in hematologic malignancies: the role of systematic reviews and meta-analysis. ActaHematol, 125, 68-79.
35. Hassan Z, Fadeel B, Zhivotovsky B, Hellström-Lindberg E (1999). Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39. ExpHematol, 27, 1322-9.
36. Hast R, Hellstrom-Lindberg E, Ohm L, et al (2003). No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia, 17, 1827-33.
37. Hellström-Lindberg E, Birgegård G, Lockner D, et al (1990). Treatmentof myelodysplastic syndromes with recombinant human erythropoietin. EurJ Haematol, 47, 355-60.
38. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A (1997). Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res, 21, 415-25.
39. Hellström-Lindberg E (1995). Efficacy of erythropoietinin the myelodysplastic syndromes. An analysis of 205 patientsin 17 studies. Br J Haematol, 89, 67-71.
40. Hellström-Lindberg E, Birgegård G, Carlsson M, et al (1993). Acombination of granulocyte-colony-stimulating factor and erythropoietinmay synergistically improve the anaemia in patients with myelodysplasticsyndromes. Leuk Lymphoma, 11, 221-8.
41. Hellström-Lindberg E, Negrin R, Stein R, et al (1997). Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol, 99, 344-51.
42. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al (1998). Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92, 68-75.
43. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al (2003). A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol, 120, 1037-46.
44. Hoffman WK, Ottman OG, Ganser F, Hoeltzer D (1996). Myelodysplatic syndromes: clinical features. SeminHematol, 33, 177-85.
45. Ikeda Y, Miyakawa Y (2009). Development of thrombopoietin receptor agonists for clinical use. J ThromHaemost, 7, 239-44.
46. Imamura M, Kobayashi M, Kobayashi S, et al (1994). Failure of combination therapy with recombinant granulocyte colonystimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol, 68, 163-6.
47. Itzykson R, Fenaux P, (2009). Optimal sequencing of treatments for patients with myelodysplastic syndromes. Curr Opin Hematol, 16, 77-83.
48. Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis T (1989). Circulating erythropoietin in patients with myelodysplastic syndrome. Br J Haematol, 73, 36-9.
49. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E (2005). Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106, 803-11.
50. Jädersten M, Malcovati L, Dybedal I, et al (2008). Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol, 26, 3607-17.
51. Kaczmarski RS, Mufti GJ (1993). Low-dose filgrastim therapy for chronic neutropenia. N Engl J Med, 329, 1280-81.
52. Kantarjian H, Giles FJ, Greenberg PL, et al (2010). Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacytidine therapy. Blood, 116, 3163-70.
53. Kantarjian H, Giles F, List A, et al (2007). The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer, 109, 1705-14.
54. Kantarjian H, Fenaux P, Sekeres MA, et al (2010). Safety and efficacy of Romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol, 28, 437-44.
55. Kizaki M, Miyakawa Y, Ikeda Y (2003). Long-term administration of Pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br J Haematol, 122, 764-7.
56. Kobayashi Y, Okabe T, Ozawa K, et al (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary rEPOrt. Am J Med, 86, 178-82.
57. Komrokji RS, Sekeres MA (2011). List AF Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep, 6, 145-53.
58. Kuter DJ (2007). New thrombopoietic growth factors. Blood, 109, 4607-16.
59. Kuter DJ, Romiplostim (2011). Cancer Treat Res, 157, 267-88.
60. Kuter DJ (2009). Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Ann Rev Med, 60, 193-206.
61. Liongue C, Wright C, Russell AP, Ward AC (2009). Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int J Bioch Cell Bio, 141, 2372-5.
62. Lyman GH, Kuderer NM, Balducci L (2002). Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol, 9, 207-14.
63. Lyons RM, Kosmo MA, Gandhi S, et al (2009). Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. American Society of Hematology annual meeting abstract number 1770.
64. Mavroudi I, Pyrovolaki K, Pavlaki K, et al (2011). Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res, 35, 323-8.
65. Ma X, Does M, Raza A, Mayne ST (2007). Myelodysplastic syndromes; incidence and survival in the United States. Cancer, 109, 1536-42.
66. Matovani L, Lentini G, Hentschel B, et al (2000). Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colonystimulating factor and erythropoietin. Br J Haematol, 109, 367-75.
67. Mavroudi I, Pyrovolaki K, Pavlaki K, et al (2011). Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res, 35, 323-8.
68. Millot GA, Svinarchuk F, Lacout C, Vainchenker W, Dumenil D (2001). The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat 5. British J Hematol, 112, 449-58.
69. Mittelman M, Oster HO, Hoffman M, Neumann D (2010). The low risk MDS patients at risk of rapid progression. Leuk Res, 34, 1551-5.
70. Miyakawa Y, Oda A, Druker BJ, et al (1996). Thrombopoietin induces thyrosin phosphorylation of Stat3 and Stat5 in human blood platelets. Blood, 87, 439-46.
71. Miyakawa Y, Oda A, Druker BJ, et al (1995). Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood, 86, 23-7.
72. Molineux G (2011). Granulocyte colony-stimulating factors. Cancer Treat Res, 157, 33-53.
73. Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S (2008). Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol, 87, 527-36.
74. Mundle S, Lefebvre P, Vekeman F, et al (2009). An assessment of erythroid response to EPOetin alpha as a single agent versus in combination with granulocyte- or granulocytemacrophage- colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer, 115, 706-15.
75. Myelodysplastic syndromes v.2 (2010). NCCN Clinical Practice Guidelines in OncologyTM. Available at: www.nccn.org.
76. Nachtkamp K, Kundgen A, Strupp C, et al (2009). Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res, 33, 1024-8.
77. Negrin RS, Stein R, Doherty K, et al (1996). Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood, 87, 4076-81.
78. Negrin RS, Haeber DH, Naler A, et al (1989). Treatment of myelodysplastic syndromes with recombinant granulocyte colony-stimulating factor. Ann Intern Med, 110, 966-84.
79. Negrin RS, Haeber DH, Nehler A, et al (1990). Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood, 76, 36-43.
80. Negrin RS, Stein R, Doherty K, et al (1996). Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin; Evidence for in vivo synergy. Blood, 87, 4076-81.
81. Negrin RS, Stein R, Doherty K, et al (1993). Treatment of the anemia of myelodysplastic syndromes using human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82, 737-43.
82. Nikamae-Akahori M, Takayuki K, Masuda S, et al (2006). Enhanced neutrophil motility by granulocyte colonystimulating factor: the role of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase, 119, 393-403.
83. Nikpour M, Pellagatti A, Liu A, et al (2010). Gene expression profiling of erythroblasts from refractory anemia with ring sideroblasts (RARS) and effects of G-CSF. Br J Hematol, 149, 844-54.
84. Nimer SD (2008). Myelodysplastic syndrome. Blood, 111, 4841-51.
85. Ohyashiki K, Ohyashik JH, Toyama K, Takaku F (1989). Hematologic and cytogentic findings in myelodysplastic syndromes treated with recombinant granulocyte colonystimulating factor. Jpn J Cancer Res, 80, 848-54.
86. Panopoulos AD, Watowich SS (2008) Granulocyte colonystimulating factor: molecular mechanisms of action during steady state and emergency hematopoiesis. Cytokine, 42, 277-88.
87. Park S, Kelaidi C, Sapena R, et al (2010). Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res, 34, 1430-36.
88. Park S, Grabar S, Kelaidi C, et al (2008). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, 111, 574-82.
89. Perugini M, Varelias A, Sadlon T, D' Andra RJ (2009). Hematopoietic growth factor mimetics: from concept to clinic. Cytokine Growth Factor Rev, 20, 87-94.
90. Philpott NJ, Prue RL, Marsh JC, Gordon-Smith EC, Gibson FM, (1997). CSF-mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: role of G-CSF as survival factor. Br J Haematol, 97, 146-52.
91. Remacha AF, Arrizabalaga B, Villegas A, et al (1999). Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica, 84, 1058-64.
92. Richards MK, Liu F, Iwasaki H, Akashi K, Link DC (2003). Pivotal role of granulocyte-stimulating factor in the development of progenitors in the common myeloid pathway. Blood, 102, 3562-68.
93. Rizzo JD, Brouwers M, Hurley P, et al (2010). American society of clinical oncology/American society of hematology clinical guideline update on the use of EPOetin and DarbEPOetin in adult patients with cancer. J ClinOncol, 28, 4996-5010.
94. Rollison DE, Howlader N, Smith MT, et al (2008). Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood, 112, 45-52.
95. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995). Theuse of r-HUEPO in the treatment of anaemia related to myelodysplasia(MDS). Br J Haematol, 89, 831-7.
96. Sanchez JF (2011). Treatment of myelodysplastic syndromes in elderly. AdvTher, 28, 1-9.
97. Santini V, Alessandrino PE, Angelucci E, et al (2010). Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO, practice guidelines. Leuk Res, 34, 1576-88.
98. Sanz GF, Sanz MA, Vallespi T, et al (1989). Two regression models and scoring system for predicting survival and planning treatment in myelodysplastic syndromes:a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395-08.
99. Schmidt-Mende J, Tehranchi R, Forsblom AM, et al (2001). Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia, 15, 742-51.
100. Sekeres MA (2011). Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw, 9, 57-63.
101. Sekeres MA (2010). Are we nearer to curing patients with MDS? Best Pract Res Clin Haematol, 23, 481-7.
102. Sekeres MA, Schoonen M, Kantarjian H, et al (2008). Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst, 100, 1542-51.
103. Sekeres MA, Fu AZ, Maciejewski JP, et al (2007). A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer, 109, 1125-32.
104. Sekeres MA, Kantarjian H, Fenaux P, et al (2011). Subcutaneous or intravenous administration of Romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer, 117, 992-1000.
105. Sloand EM, Yong AS, Ramkissoon S, et al (2006). Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA, 103, 14483-8.
106. Silva M, Grillot D, Benito A, et al (1996). Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood, 88, 1576-82.
107. Smith TJ, Khatcheressian J, Lyman GH, et al (2006). Updates of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol, 24, 3187-205.
108. Stasi R, Bosworth J, Rhodes E, Shannon MS (2010). Thrombopoietic agents. Blood Rev, 24, 179-90.
109. Steensma DP, Bennett JM (2006). The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc, 81, 104-30.
110. Steinbrook R (2007). Erythropoietin, the FDA, and oncology. N Engl J Med, 356, 2448-51.
111. Stone RM (2009). How I treat patients with myelodysplastic syndromes. Blood, 113, 6296-303.
112. Sung L, Dror Y (2007). Clinical applications of granulocytecolony stimulating factor. Front Biosci, 12, 1988-2002.
113. Tehranchi R, Fadeel B, Forsblom AM, et al (2003). Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101, 1080-10.
114. Tehranchi R, Fadeel B, Schmidt-Mende J, et al (2005). Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res, 11, 6291-9.
115. Tefferi A, Vardiman JW (2009). Myelodyspalstic syndromes. N Engl J Med, 361, 1872-85.
116. Tefferi A (2010). Myelodysplastic syndromes-many new drugs, little therapeutic progress. Mayo ClinProc, 85, 1042-5.
117. Terpos E, Mougiou A, Kouraklis A, et al (2002). Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol, 118, 174-80.
118. Uddin S, Kottegoda S, Stigger D, Platanias LC, Wickrema A (2000). Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. Biochem Biophys Res Commun, 275, 16-9.
119. Vadhan-Raj S, Keating M, LeMaistre A, et al (1987). Effects of recombinant human granulocyte-macrophage colonystimulating factor in patients with myelodysplastic syndromes. N Engl J Med, 317, 1545-52.
120. Vardiman JW, Thiele J, Arber DA, et al (2009). The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute. Leukemia: rationale and important changes. Blood, 114, 937-51.
121. Verbeek W, Wormann B, Koch P, et al (1997). S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol, 74, 205-8.
122. Ward AC (2007). The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci, 12, 608-18.
123. Watson RW, O'Neill A, Brannigen AE, et al (1999). Regulation of Fas antibody induced neutrophil apoptosis is both caspase and mitochondrial dependent. FEBS Lett, 453, 67-71.
124. Westers TM, Alhan C, Chamuleau ME, et al (2010). Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood, 115, 1779-84.
125. Yoshida Y, Hirashima K, Asano S, Takaku F (1991). A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol, 78, 378-84.
126. You A, Kitagawa S, Okabe T, et al (1987). Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myeloid leukemia. Blood, 70, 404-11.